Related Experiment Video
Updated: May 20, 2025

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment
Published on: June 9, 2023
Piperlongumine Inhibits Malignant Progression of Esophageal Squamous Cells Through the PI3K/AKT Signaling Pathway
Jun Wang1, Yueming Chu2, Guangbing Hu1
1Department of Gastroenterology, Affiliated Hospital of North Sichuan Medical College, Nanchong, 637000, Sichuan, China.
Abstract:
To examine the impact of Piperlongumine (PL) on the proliferation, migration, invasion, cell cycle progression, and apoptosis in esophageal squamous cell carcinoma (ESCC) cells, as well as to elucidate the underlying molecular mechanisms. The suppressive effects of PL on the viability of ESCC cells were assessed using the CCK-8 assay, bright field imaging, and colony formation assays. Apoptosis induction and cell cycle disruption by PL were evaluated using flow cytometry. The impact of PL on ESCC cell migration and invasion was examined through scratch healing and Transwell assays. Differential gene expression analysis of ESCC tumor and normal tissues from the GSE29886 dataset, integrated with network pharmacology predictions, was conducted to identify core genes and molecular mechanisms involved in PL action. Key protein expression levels in the apoptosis, epithelial-mesenchymal transition (EMT), and PI3K/AKT signaling pathways were quantified by Western blotting. The CCK-8 and colony formation assays demonstrated that PL effectively suppressed cell viability and proliferation in ESCC. Flow cytometry revealed that PL down-regulated CDK1 expression, resulting in G2/M phase arrest, and promoted apoptosis by decreasing Bcl-2 levels and increasing cleaved caspase-3 and PARP. The scratch and Transwell assays indicated that PL inhibited ESCC cell migration and invasion, down-regulated the EMT-associated proteins Vimentin and N-cadherin, and up-regulated E-cadherin. Western blotting confirmed the down-regulation of P-PI3K and P-AKT, indicating the inhibition of the PI3K/AKT pathway by PL. These findings offer a pharmacological foundation for the development of PL as a potential phytotherapeutic agent for the clinical management of ESCC.
Insights
Piperlongumine (PL) effectively inhibits esophageal squamous cell carcinoma (ESCC) growth by suppressing proliferation, migration, and invasion. It also induces apoptosis and cell cycle arrest, offering potential as a phytotherapeutic agent for ESCC.
Area of Science:
- Oncology
- Pharmacology
- Molecular Biology
Background:
- Esophageal squamous cell carcinoma (ESCC) is a significant global health concern.
- Effective therapeutic strategies for ESCC remain a critical unmet need.
- Piperlongumine (PL) is a natural compound with potential anti-cancer properties.
Purpose of the Study:
- To investigate the anti-cancer effects of Piperlongumine (PL) on esophageal squamous cell carcinoma (ESCC) cells.
- To elucidate the molecular mechanisms underlying PL's action in ESCC.
- To evaluate PL as a potential phytotherapeutic agent for ESCC treatment.
Main Methods:
- Cell viability, proliferation, apoptosis, and cell cycle assays (CCK-8, colony formation, flow cytometry).
- Migration and invasion assays (scratch healing, Transwell).
- Bioinformatic analysis (GSE29886 dataset, network pharmacology) and Western blotting for key protein expression (EMT, PI3K/AKT pathways).
Main Results:
- PL significantly suppressed ESCC cell viability, proliferation, migration, and invasion.
- PL induced G2/M phase cell cycle arrest by down-regulating CDK1 and promoted apoptosis by modulating Bcl-2, cleaved caspase-3, and PARP.
- PL inhibited EMT by down-regulating Vimentin and N-cadherin while up-regulating E-cadherin, and suppressed the PI3K/AKT pathway.
Conclusions:
- Piperlongumine exhibits potent anti-cancer effects against ESCC by targeting multiple cellular processes and signaling pathways.
- PL demonstrates significant potential as a phytotherapeutic agent for the clinical management of esophageal squamous cell carcinoma.
- Further research into PL's mechanisms and clinical efficacy is warranted.
Related Concept Videos
PI3K/mTOR/AKT Signaling Pathway
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Abnormal Proliferation
Mitogens and the Cell Cycle
The JAK-STAT Signaling Pathway
Inhibition of Cdk Activity

